interleukin-6 – Page 49 – Communicable Diseases Research

Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads

Review

Published on 2020-10-012023-07-06
Journal: Journal of the Renin-Angiotensin-Aldosterone Syste [Category] SARS,

How COVID-19 induces cytokine storm with high mortality

Review

Published on 2020-10-012022-10-30
Journal: Inflammation and Regeneration [Category] COVID-19,

Appropriate use of tocilizumab in COVID-19 infection

Article

Published on 2020-10-012023-07-07
Journal: International Journal of Infectious Diseases [Category] SARS,

[키워드] COVID-19 Cytokines interleukin-6 therapy Tocilizumab
[DOI] 10.1016/j.ijid.2020.07.036 PMC 바로가기

SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region

신장 이식 환자의 SARS-CoV-2 감염: 이탈리아 행진 지역의 경험

Article

Published on 2020-10-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, 진단, 치료제,

[키워드] acute respiratory syndrome Administered administration Admission affecting AKI Ancona best biochemical calcineurin caused Clinical data clinical monitoring concomitance country Critical CRRT Cytosorb D-dimer death discharged dose drop Efficacy experience hospital Hydroxychloroquine ICU Immunosuppression incidence Infection inhibitors interleukin-6 interleukin-6 receptor Intubated Italy kidney kidney transplant Laboratory low-dose Marche Mortality mTOR outcome oxygen oxygen saturation pandemic Patient patients died physician Preliminary data present Prevalence receptor antagonist reduction reported respiratory SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severity significant increase Steroids the timing Tocilizumab treated Treatment two patients virus
[DOI] 10.1111/tid.13377 PMC 바로가기 [Article Type] Article

Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses

Research Article

Published on 2020-09-172022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] alanine aminotransferase Analysis Aspartate aminotransferase association associations build C-reactive protein Characteristics clinical Clinical practice Computed tomography consolidation contributed cough COVID-19 COVID-19 pandemic D-dimer disease disease severity Dyspnea Effect elevated eligible erythrocyte sedimentation rate Evidence explained fatigue Fever gastrointestinal symptoms Ground glass opacity heterogeneity heterogeneous hospitalized patients identify Infection interleukin-6 investigator Laboratory LILACS Lymphocytes lymphocytopenia Male sex meta-analyses Meta-analysis meta-regression New non-specific Novel coronavirus Older age other variable outcome Patient Platelets Pneumonia Prevalence radiological Risk of bias SARS-CoV-2 searched septal thickening severe disease Severity of disease sore throat Study design systematic review variable was used White blood cell
[DOI] 10.1371/journal.pone.0239235 PMC 바로가기 [Article Type] Research Article

Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital

Pharmacology

Published on 2020-09-162022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] Admission allergic disease allergy analyzed Asthma blocker clinical clinical evolution Clinical outcome co-morbidities collected Comorbidity consecutive patient Coronavirus disease 2019 D-dimer value disorder finding hospital Hospital stay Hospitalization Hospitalized ICU individual inhibitor intensive care unit interleukin-6 Laboratory less leukocyte Mortality Older age oral anticoagulant outcomes oxygen saturation Patient patients radiological radiological finding reported risk selective serotonin reuptake inhibitor severe acute respiratory syndrome coronavirus 2 Spain Spanish susceptibility Symptoms therapy Treatment university
[DOI] 10.3389/fphar.2020.570721 PMC 바로가기 [Article Type] Pharmacology

Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019

Correspondence

Published on 2020-09-112022-11-01
Journal: Cellular and Molecular Immunology [Category] COVID-19, MERS, SARS,

[키워드] coronavirus disease Critical Infection interleukin-6 Prognostic markers
[DOI] 10.1038/s41423-020-00522-6 PMC 바로가기 [Article Type] Correspondence

Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay

Methodology

Published on 2020-09-102022-10-29
Journal: Journal of Nanobiotechnology [Category] Coronavirus, SARS,

[키워드] accelerate analyzed antibody assays Biomarker C-reactive protein C-reactive protein (CRP caused clinically complex Conjugation chemistry consequence Conventional COVID-19 CRP Cytokine storm Diagnosis diagnostics Duplex lateral flow assay event events FIVE Gold nanoparticle handling IL-6 Image processing ImageJ immunoassay include Infection Inflammation Inflammatory information intensities interleukin-6 lateral flow limits medical need Multiplexing Nanoparticles optical pathophysiology POC point-of-care point-of-care diagnostics powerful tool provide quantification Quantitative quantum dots R-package Sandwich immunoassay Sensitivity and specificity Sepsis Shiny app target protein targets test line Treatment was used were used
[DOI] 10.1186/s12951-020-00688-1 PMC 바로가기 [Article Type] Methodology

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

Position article and Guidelines

Published on 2020-09-042022-10-31
Journal: Military Medical Research [Category] COVID-19, Fulltext, SARS,

[키워드] 2019 novel coronavirus 2019-nCoV acute respiratory syndrome affecting antibody tests antiviral drugs approach assessment asymptomatic infections Chemoprophylaxis Chest Chest computed tomography Chinese clinical manifestations Clinical practice clinician Combination convalescent plasma coronavirus coronavirus disease COVID-19 COVID-19 patients criteria develop development Diagnosis discharge discharge management early stage Evidence extracorporeal membrane oxygenation Favipiravir feature glucocorticoid healthcare worker help hydroxychloroquine/chloroquine IgM and IgG implementation inhibitors interferon interleukin-6 invasive Lopinavir-ritonavir lung management Medicine Noninvasive ventilation Patient Pneumonia positive question recommendation Remdesivir respiratory tract specimens RT-PCR SARS-CoV-2 searched Support TCM Traditional Traditional Chinese medicine; guideline Treatment treatment guideline umifenovir
[DOI] 10.1186/s40779-020-00270-8 PMC 바로가기 [Article Type] Position article and Guidelines

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hours absence Admission all-cause mortality Arm blinded chest imaging clinical commenced Confirmed COVID-19 criteria CRP D-dimer Data analysis database death defined demonstrated determine disease dissemination dose Efficacy element eligible participant enrolled EudraCT Evidence evidence of evidenced facilitate ferritin fibrinogen hospital humanized monoclonal antibody hyper-inflammation IL-6 IL6 immunology independent Infection inflammatory state infused inhibit interleukin-6 intravenous tocilizumab intubation investigators Ireland LDH low dose management Mater moderate to severe multicentre non-invasive ventilation number objective Older open label outcome PaO participant Patient patients with COVID-19 PCR-confirmed COVID-19 performed positive PCR Potential treatment primary endpoint Primary outcome progression protocol pulmonary randomisation randomised randomised controlled trial Randomised trial receive recruited reduced Registered reported Respiratory failure Respiratory function Sample size SARS-CoV2 infection single dose Stage stage 2 Standard Standard dose status Study protocol subject subjects subsequent systemic inflammation target temperature Therapeutics Tocilizumab treatment group Trial ULN university Ventilation website
[DOI] 10.1186/s13063-020-04680-w PMC 바로가기 [Article Type] Letter